Recently, co-mutation of TP53 with other oncogenes such as RAS or BRAF has been associated with significantly worse prognosis than mutations in RAS or TP53 alone in patients undergoing curative-intent metastasectomy of metastatic colorectal cancer [15]. The gene discussed is TP53; the disease is metastatic colorectal cancer.